

Special Issue

Preclinical Models for Novel Drug Combination in Advanced Ovarian Cancer

Message from the Guest Editor

Advanced ovarian cancer is predominantly fatal and imposes a significant health burden on patients' quality of life. Despite notable advancements in drug discovery, options for drug treatment at advanced stages remain limited, albeit viable clinical trials have emerged. The PARP inhibitor family stands out as a well-recognized treatment for patients exhibiting abnormal BRCA gene functions. Additionally, antiangiogenic drugs have shown promise in enhancing the efficacy of conventional platinum and Taxane regimens. However, the failure rate of this combination regimen, involving both PARP inhibitors and antiangiogenic blockers, remains high. Such ineffectiveness underscores the challenges inherent in the ongoing drug discovery pipeline for ovarian cancer. Hence, this Special Issue on ovarian cancer will primarily focus on novel drug combinations validated in preclinical models. The potential of these novel combinations presents an exciting avenue, potentially leading to the discovery of potent drug combination therapies that can undergo clinical trials.

Guest Editor

Dr. Kenny Chitcholtan

Gynaecological Cancer Research Group, Department of Obstetrics and Gynaecology, University of Otago Christchurch, Christchurch 8011, New Zealand

Deadline for manuscript submissions

closed (30 November 2024)



International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/205459

*International Journal of
Molecular Sciences*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ijms@mdpi.com

[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)





International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)



About the Journal

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences,
Sez-Biochimica, Faculty of Medicine, Università Politecnica delle
Marche, Via Ranieri 65, 60100 Ancona, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore
- Q1 (Organic Chemistry)